Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43884   clinical trials with a EudraCT protocol, of which   7296   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004091-34
    Sponsor's Protocol Code Number:CCR3972
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:GB - no longer in EU/EEA
    Date on which this record was first entered in the EudraCT database:2014-03-27
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2013-004091-34
    A.3Full title of the trial
    A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A trial of the combination treatment enzalutamide and AZD5363 for patients with advanced prostate cancer.
    A.3.2Name or abbreviated title of the trial where available
    RE-AKT
    A.4.1Sponsor's protocol code numberCCR3972
    A.5.4Other Identifiers
    Name:ICR-CTSU numberNumber:lCR-CTSU/2012/10037
    Name:Cancer Research UK Reference NumberNumber:CRUKE/12/050
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorThe Royal Marsden NHS Foundation Trust
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca UK Limited
    B.4.2CountryUnited Kingdom
    B.4.1Name of organisation providing supportAstellas Pharma Ltd
    B.4.2CountryUnited Kingdom
    B.4.1Name of organisation providing supportCancer Research UK Endorsement
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationThe Institute of Cancer Research
    B.5.2Functional name of contact pointAlexa Gillman
    B.5.3 Address:
    B.5.3.1Street Address15 Cotswold Road
    B.5.3.2Town/ citySutton
    B.5.3.3Post codeSM25NG
    B.5.4Telephone number02087224188
    B.5.6E-mailRE-AKT-icrctsu@icr.ac.uk
    B.Sponsor: 2
    B.1.1Name of SponsorThe Institute of Cancer Reseacrh
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationThe Institute of Cancer Research
    B.5.2Functional name of contact pointAlexa Gillman
    B.5.3 Address:
    B.5.3.1Street Address15 Cotswold Road
    B.5.3.2Town/ citySutton
    B.5.3.3Post codeSM25NG
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number02087224188
    B.5.6E-mailRE-AKT-icrctsu@icr.ac.uk
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Xtandi
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEnzalutamide
    D.3.2Product code N/A
    D.3.4Pharmaceutical form Capsule, soft
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEnzalutamide
    D.3.9.1CAS number 915087-33-1
    D.3.9.2Current sponsor codeN/A
    D.3.9.3Other descriptive nameN/A
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAZD5363
    D.3.2Product code AZD5363
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZD5363
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZD5363
    D.3.9.4EV Substance CodeAS3
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Castration- Resistant Prostate Cancer
    E.1.1.1Medical condition in easily understood language
    Cancer of the prostate that is advanced
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level PT
    E.1.2Classification code 10062904
    E.1.2Term Hormone-refractory prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase I safety run in
    To find out how safe and how well tolerated the combination treatment of enzalutamide and AZD5363 is.
    To estimate the maximum dose of AZD5363 that is tolerated in combination with enzalutamide.
    To identify the dose of AZD5363 to use in the combination treatment in the randomised phase II trial.

    Randomised phase II
    To measure the response to AZD5363 + enzalutamide and placebo + enzalutamide.
    To compare the responses to AZD5363 + enzalutamide and placebo + enzalutamide.

    Single stage phase II expansion cohort
    To measure the response to AZD5363 + enzalutamide
    E.2.2Secondary objectives of the trial
    SECONDARY OBJECTIVES

    Phase I safety run in
    To find out the what the body does to the drugs (pharmacokinetics) when AZD5363 and enzalutamide are given in combination.
    To measure the response of the combination treatment by using images to assess the cancer and looking at the changes in the blood (CTC evaluation and PSA).

    Randomised phase II and single stage phase II expansion cohort
    To assess progression free survival using images to assess the spread of the cancer; overall survival; number of bone fractures; looking at the changes in the blood (CTC evaluation and PSA) and to changes in the amount of pain reported (using BPI-SF). Also to find out how safe and well tolerated the combination treatment is compared to placebo + enzalutamide.

    EXPLORATORY OBJECTIVES

    Phase I safety run in and Single Stage Phase II Expansion
    To find out what the combination treatment does to the body (pharmacodynamics)

    Randomised phase II and Single Stage Phase II Expansion
    To look at ho
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1)Written informed consent.
    2)Histological diagnosis of adenocarcinoma of the prostate and with archival tumour tissue
    3)Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    4)Progressed after 1 or 2 lines of taxane based chemotherapy.
    5)Progressed after at least 12 weeks of abiraterone
    6)Age 18 years or above.
    7)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
    8)PSA greater than or equal to 10ng/ml.
    9)Documented willingness to use an effective means of contraception while participating in the study and for 12 months post last dose of treatment
    10)Documented ongoing castrate serum testosterone <50 ng/dL (<2.0 nM).
    11)Received prior castration by orchiectomy and/or ongoing Luteinizing Hormone-Releasing Hormone (LH-RH) agonist treatment.
    12)Progression of disease by PSA utilizing PCWG2 criteria and at least another of the following criteria;
    a.disease progression as defined by at least 2 new lesions on bone scan.
    b.Soft tissue disease progression defined by modified RECIST 1.1.
    c.Clinical progression (worsening pain & the need for palliative radiotherapy).

    PHASE I SAFETY RUN IN and EXPANSION COHORT - inclusion criteria:
    13)Willing to have a biopsy to obtain tumour tissue for biomarker analyses prior to and after treatment.

    SINGLE STAGE PHASE II EXPANSION COHORT ONLY - inclusion criteria:
    14)Prior exposure to enzalutamide of at least 12 weeks is required with documented disease progression
    15)Archival tumour tissue available for the analysis of PTEN loss by the central laboratory
    E.4Principal exclusion criteria
    1)Prior treatment with enzalutamide (not applicable for the phase I safety run in or for the single stage phase II expansion cohort).
    2)Prior treatment with PI3K, AKT, TOR kinase or mTOR inhibitors
    3)Surgery, chemotherapy, or other anti-cancer therapy within 4 weeks prior to trial entry / randomisation into the study (6 weeks for bicalutamide). Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (e.g., finasteride or dutasteride), must be discontinued at least 2 weeks before the first dose of study drug.
    4)Participation in another clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry / randomisation.
    5)Prior limited field radiotherapy within 2 weeks or wide field radiotherapy within 4 weeks of trial entry / randomisation.
    6)History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumours, brain metastases, or alcoholism.
    7)History of loss of consciousness or transient ischemic attack within the previous 12 months of trial entry / randomisation.
    8)Known brain or leptomeningeal involvement.
    9)Use of potent inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 within 2 weeks before trial entry / randomisation (3 weeks for St John¡¯s Wort) must be avoided.
    10)Clinically significant abnormalities of glucose metabolism as defined by any of the following:
    a.Diagnosis of diabetes mellitus type I or II
    b.Glycosylated haemoglobin (HbA1C) ≥8.0% at screening
    c.Fasting Plasma Glucose ≥8.9mmol/L at screening.
    11)Inadequate organ and bone marrow function as evidenced by:
    a.Haemoglobin <8.5 g/dL
    b.Absolute neutrophil count <1.0 x 109/L
    c.Platelet count < 75 x 109/L
    d.Albumin ≤25 g/dL.
    e.AST / SGOT and/or ALT / SGPT ≥ 2.5 x ULN (≥5 x ULN if liver metastases)
    f.Total bilirubin ≥ 1.5 x ULN (except for patient with Gilbert's disease)
    g.Serum Creatinine > 1.5 x ULN
    12)Inability or unwillingness to swallow oral medication.
    13)Malabsorption syndrome or other condition that would interfere with enteral absorption.
    14)Any of the following cardiac criteria;
    a.Mean resting corrected QT interval (QTcF) >470msec obtained triplicate ECGs
    b.Clinically important abnormalities(rhythm/conduction/morphology)resting ECG
    c.Factors that increase risk of QTc prolongation or risk of arrhythmic events
    d.Experience of any of the following in the preceding six months:
    - coronary artery bypass graft
    - angioplasty
    - vascular stent
    - myocardial infarction
    - angina pectoris
    - congestive heart failure NYHA ≥ Grade2
    e.Uncontrolled hypotension
    15)Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
    16)Any other finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patients at high risk from treatment complications.
    17)Need for chronic corticosteroid therapy of >10 mg of prednisolone or >0.5mg of dexamethasone per day or an equivalent dose of other anti inflammatory corticosteroid.
    18)Malignancies other than prostate cancer within 5 years prior to trial entry / randomisation, except for adequately treated basal or squamous cell skin cancer.
    19)Unresolved clinically significant toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy.
    20)Inability to comply with study and follow up procedures.
    E.5 End points
    E.5.1Primary end point(s)
    PHASE I - SAFETY RUN IN:

    - Type according to MedDRA (Medical Dictionary for Regulatory Activities), frequency and severity according to NCICTCAE V4, seriousness, and relatedness of study treatment-emergent adverse events will be assessed.
    - Laboratory abnormalities will be assessed according to the NCI CTCAE v.4.


    RANDOMISED PHASE II:

    - The primary endpoint of best overall tumour response will be defined on the basis of the following outcomes; if any of these occur without contrary evidence from any other of the other criteria patients will be considered to have responded:
    - PSA decline of ≥ 50% (according to the PCWG2)
    - Confirmed objective response (complete &/or partial response) by RECIST v1.1
    - ONLY for patients with detectable CTC of ≥5/7.5ml blood at baseline, conversion of CTC to <5/7.5ml blood nadir.

    Failure of treatment will be defined as progression by RECIST (v1.1) and/or progression by bone scan. The PCWG2 and RECIST (v1.1) criteria will be used to determine PSA response and soft tissue response respectively.


    SINGLE STAGE PHASE II EXPANSION COHORT:

    Best overall response after the addition of AZD5363 in patients who progress after 12 weeks of enzalutamide alone will be defined on the basis of the following outcomes. If any of these occur without contrary evidence from any other of the other criteria patients will be considered to have responded:

    - PSA decline of ≥ 50% after at least 12 weeks (according to the PCWG2 criteria) - - Confirmed objective response (complete and/or partial response) by RECIST v1.1
    - ONLY for patients with detectable circulating tumour cell count (CTC) of ≥5/7.5ml blood at baseline, conversion of CTC to <5/7.5ml blood nadir.

    Failure of treatment will be defined as progression by RECIST and/or progression by bone scan. PSA response and PSA progression (for the addition of AZD5363 on the single stage expansion cohort) will be defined according to the consensus guidelines of the PCWG2.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase I – safety run in: when all 18 (approximately) patients have received 12 weeks of trial treatment or they have progressed prior to that or have withdrawn before this due to unacceptable toxicity.

    Randomised Phase II : Once all patients have been evaluated 12 weeks post randomisation or have progressed prior to that, and after the data have been through quality control checks. This strategy will be reviewed by the IDMC in light of PFS events and the likely duration of response. If the target of accrued events (n=70) has not been reached by the time of the primary analysis an additional analysis will take place once these have been observed.

    Single Stage Expansion cohort: Once 13 patients have completed 12 weeks of combination treatment.
    E.5.2Secondary end point(s)
    Phase I – safety run in:

     Pharmacokinetic assay analyses.
     Antitumour activity of the combination.
     Pharmacodynamic assay analyses (tertiary/ exploratory endpoint)

    Randomised Phase II:

     Radiographic progression-free survival (rPFS- according to PCWG2 criteria & RECIST v1.1) measured from date of randomisation until:

    • Bone scan progression- a patient is considered to have progressed by bone scan if:
    i.The first bone scan with ≥2 new lesions compared to baseline is observed at 12 weeks from randomization and is confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline).
    ii. A bone scan obtained later than the 12 week assessment shows ≥2 new lesions.
    • Progression of soft tissue lesions measured by CT or MRI
    • Death from any cause
    If a patient is withdrawn for any reason prior to radiological progression then the patient should be assessed until radiological progression has occurred. If however they have started another treatment then they will be censored at the start of the new treatment.

     Overall survival measured from the date of randomisation to the date of death (whatever the cause). Survival time of living patients will be censored on the last date a patient is known to be alive or lost to follow up.

     Number of skeletal-related events defined as either the use of external beam radiotherapy to relieve skeletal symptoms or the occurrence of new symptomatic bone fractures (vertebral or non-vertebral) or the occurrence of spinal cord compression or a tumour related orthopaedic surgical intervention.

     Maximum PSA decline at any time during the trial and PSA decline at 12 weeks (as per PCWG2 criteria) presented as a waterfall plot.

     Circulating Tumour Cell (CTC) fall by >30%: This will be expressed as the proportion of patients that have demonstrated a CTC fall of >30%. Also the maximum CTC decline at any time during the trial and CTC decline at 12 weeks will be presented as a waterfall plot.

     Pain palliation will be assessed using the BPI-SF worst pain intensity score. Standard scoring algorithms will be used with a focus on worst pain intensity score and analgesic score. A composite of the four pain items (worse, least, average, right now) will be presented as supplemental information.

     Safety: Using the safety population the extent of exposure of study drug will be summarised. Adverse events will be graded according to NCI-CTCAEv4.


    Single Stage Expansion cohort:

     Maximum PSA decline at any time during the trial and PSA decline after 12 weeks (as per PCWG2 criteria) of combination treatment will be presented as a waterfall plot.
     Overall survival: It will be measured from the date of AZD5363 addition to enzalutamide to the date of death (whatever the cause). Survival time of living patients will be censored on the last date a patient is known to be alive or lost to follow up.
     Radiographic progression-free survival (rPFS) measured from the date of AZD5363 addition to enzalutamide until:
    • Bone scan progression: A patient is considered to have progressed by bone scan if:
    i.The first bone scan with ≥2 new lesions compared to baseline is observed at 12 weeks from randomization and is confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline).
    ii.A bone scan obtained later than the 12 week assessment shows ≥2 new lesions.
    • Progression of soft tissue lesions measured by CT or MRI as defined by RECIST v1.1.
    • Death from any cause.
    If a patient is withdrawn for any reason prior to radiological progression then the patient should be assessed until radiological progression has occurred. If however they have started another treatment then they will be censored at the start of the new treatment.

     CTC fall by >30% will be expressed as the proportion of patients that have demonstrated a CTC fall of >30% after 12 weeks of combination treatment.

     Safety: Using the safety population the extent of exposure of study drug will be summarised. Adverse events will be graded according to NCI-CTCAEv4.

     Pharmacodynamic assay analyses (tertiary/ exploratory endpoint)

    E.5.2.1Timepoint(s) of evaluation of this end point
    Phase I – safety run in: when all 18 (approximately) patients have received 12 weeks of trial treatment or they have progressed prior to that or have withdrawn before this due to unacceptable toxicity.

    Randomised Phase II : Once all patients have been evaluated 12 weeks post randomisation or have progressed prior to that, and after the data have been through quality control checks. This strategy will be reviewed by the IDMC in light of PFS events and the likely duration of response. If the target of accrued events (n=70) has not been reached by the time of the primary analysis an additional analysis will take place once these have been observed.

    Single Stage Expansion cohort: Once 13 patients have completed 12 weeks of combination treatment.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    First administration of enzalutamide and AZD5363 in combination.
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial is the defined as the last date of data capture.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 48
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 90
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state136
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 136
    F.4.2.2In the whole clinical trial 136
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will continue on study treatment until disease progression (until they are no longer receiving any benefit from treatment). The continued care of patients will be at the discretion of their treating physician once they are off
    study.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-03-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-03-19
    P. End of Trial
    P.End of Trial StatusGB - no longer in EU/EEA
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA